- Home
- APRE vs HSCS Comparison
APRE vs HSCS Comparison
Compare APRE & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- HSCS
- Stock Information
- Founded
- APRE 2006
- HSCS 2007
- Country
- APRE United States
- HSCS United States
- Employees
- APRE N/A
- HSCS N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- HSCS Medical Specialities
- Sector
- APRE Health Care
- HSCS Health Care
- Exchange
- APRE Nasdaq
- HSCS Nasdaq
- Market Cap
- APRE 9.4M
- HSCS 8.7M
- IPO Year
- APRE 2019
- HSCS 2022
- Fundamental
- Price
- APRE $1.54
- HSCS $3.01
- Analyst Decision
- APRE Strong Buy
- HSCS Strong Buy
- Analyst Count
- APRE 1
- HSCS 2
- Target Price
- APRE $20.00
- HSCS $13.00
- AVG Volume (30 Days)
- APRE 34.4K
- HSCS 83.1K
- Earning Date
- APRE 11-06-2025
- HSCS 09-11-2025
- Dividend Yield
- APRE N/A
- HSCS N/A
- EPS Growth
- APRE N/A
- HSCS N/A
- EPS
- APRE N/A
- HSCS N/A
- Revenue
- APRE $841,012.00
- HSCS $6,250.00
- Revenue This Year
- APRE N/A
- HSCS $13,968.97
- Revenue Next Year
- APRE N/A
- HSCS $166.67
- P/E Ratio
- APRE N/A
- HSCS N/A
- Revenue Growth
- APRE N/A
- HSCS N/A
- 52 Week Low
- APRE $1.41
- HSCS $2.52
- 52 Week High
- APRE $5.01
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- APRE 43.27
- HSCS 35.68
- Support Level
- APRE $1.49
- HSCS $3.22
- Resistance Level
- APRE $1.66
- HSCS $3.49
- Average True Range (ATR)
- APRE 0.08
- HSCS 0.20
- MACD
- APRE 0.00
- HSCS -0.02
- Stochastic Oscillator
- APRE 27.00
- HSCS 0.78
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.